Merck's Dec 9th aquisition of ArQule(ARQL) is a case that RVX and Zenith shareholders should be aware of. Talks with a number of companies had been going on for almost 2 years when the last one said lets make a deal. Before you knew it ARQL which had been under $3 a share 11 months and a couple of weeks earlier, because of tax loss selling, got bought out for $20 per share or $2.7 billion. ARQL was a Phase I company that had had a couple of failures.

My point, it can and does happen. Apabetalone has a lot going for it in some very large markets.

Read the story if you haven't already. There are a number of similarities to our stories.

https://endpts.com/after-being-repeatedly-jilted-this-biotech-was-swept-off-its-feet-in-a-race-to-ash-inside-mercks-2-7b-arqule-buyout/

tada